Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-08-15
2006-08-15
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S185100, C424S191100, C424S265100, C424S270100, C435S069100, C435S069700, C536S023100, C536S023400
Reexamination Certificate
active
07090849
ABSTRACT:
The present invention relates to nucleic acid sequences encoding novelBabesia canisassociated proteins and to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Furthermore, the invention relates to host cells comprising such nucleic acid sequences, cDNA fragments, recombinant DNA molecules and live recombinant carriers. Also, the invention relates to proteins encoded by these nucleotide sequences, to vaccines for combatingBabesia canisinfections comprising these proteins or genetic material encoding these proteins and methods for the preparation of vaccines. Another embodiment of the invention relates to theseBabesia canisassociated proteins for use in vaccines and to the use of theBabesia canisassociated proteins in the manufacture of vaccines. Finally the invention relates to diagnostic tools for the detection ofBabesia canisassociated nucleic acid sequences, for the detection ofBabesia canisassociated antigens and for the detection of antibodies againstBabesia canisassociated antigenic material.
REFERENCES:
patent: 6045806 (2000-04-01), Schetters
patent: 0 691 131 (1996-01-01), None
patent: 1 050 541 (2000-11-01), None
Kulakov et al 1998 Molekulyarnaya Genetika, Microbiologiya i virusologiya (2), 7-13 (abstract only).
Schetters et al 1992 (Parasite Immunology 1992, 14(3) 295-305 abstract only).
(Burgess et al., The Journal of Cell Biology, 111:2129-2138, 1990).
Schetters T P M et al: “Can Babesia infections be used as a Model for Cerebral Malaria?”, Parasitology Today, vol. 15, No. 12, Dec. 1999, pp. 492-497.
Carcy B et al: “A 37-kilodalton glycoprotein of Babesia divergens is a major component of a protective fraction containing low-molecular-mass culture-derived exoantigens”, Infection and Immunity, American Society for Microbiology, Washington, US, vol. 63, No. 3, Mar. 1995, pp. 811-817.
Grande N et al: “Comparison between aseric and seric culture-derived exoantigens of Babesia divergens in their ability to induce immunoprotection in gerbils”, Parasitology International, Elsevier Science, Amsterdam, NL. vol. 47, No. 4, Dec. 1998, pp. 269-279.
Carret Celine et al: “Characterization and molecular cloning of an adenosine kinase fromBabesia canis rossi,” European Journal of Biochemistry, vol. 265, No. 3, Nov. 1999, pp. 1015-1021.
Carret Celine et al: “Babesia canis canis, Babesia canis vogeli, Babesia canis rossi: Differentiation of the three subspecies by a restriction fragment length polymorphism analysis on amplified small subunit ribosomal RNA genes,” Journal of Eukaryotic Microbiology, vol. 46, No. 3, May 1999, pp. 298-303.
Carcy Bernard Pierre Dominique
Drakulovski Pascal Robert
Schetters Theodorus Petrus Maria
Akzo Nobel N.V.
Baskar Padma
Ramey III William P.
Schwartz Aaron L.
Smith Lynette R. F.
LandOfFree
Babesia canis vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Babesia canis vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Babesia canis vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3675170